Latest Development Programs News

BluGlass has embarked on a A$1.25 million development program with a major US defence prime, receiving an initial A$560,000 order to develop cutting-edge visible GaN lasers for aerospace and defence applications.

Tivan Limited has committed up to $1 million over four years to support Indigenous communities through a partnership with the Central Land Council, reinforcing its responsible mining approach in Central Australia.

Provaris Energy has successfully raised $1.325 million through an oversubscribed placement, aiming to advance its 2026 development milestones in hydrogen and carbon dioxide storage technologies.

Aurum Resources reports multiple broad, shallow, high-grade gold intercepts from its 30,000m drilling program at the Napié Gold Project in Côte d’Ivoire, underpinning an imminent resource update and growth strategy. The company’s dual-asset approach and strong balance sheet position it for a pivotal transition from explorer to developer in 2026.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

PYC Therapeutics has successfully closed its retail entitlement offer, raising approximately $47 million at $1.50 per new share with a 40% take-up rate. New shares are set to begin trading on the ASX from 9 March 2026.

Cobalt Blue Holdings has confirmed its cobalt sulphate meets stringent battery precursor specifications, advancing its Kwinana Cobalt Refinery toward a Final Investment Decision. The company also expands its graphite recovery program, positioning itself at the forefront of Australia’s battery materials ecosystem.

Carnaby Resources has reported a standout drill result of 18 metres at 5.0% copper equivalent at its Trek 2 prospect, signalling significant growth potential beyond current resource estimates at the Greater Duchess Copper Gold Project.

Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.

Nanoveu Limited reported a dramatic revenue increase driven by its strategic acquisition of Embedded A.I. Systems, while losses widened as it invests heavily in semiconductor commercialisation. The company’s recent $7.5 million capital raise aims to fuel its next growth phase.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

Beacon Minerals Limited has reported a robust half-year performance with gold sales more than doubling to AU$82.6 million and a comprehensive profit of AU$14.8 million, driven by strong production growth and higher gold prices.